Day: May 7, 2025

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2025. Management commentary “Sprott’s Assets Under Management (“AUM”) ended the first quarter of 2025 at $35.1 billion, up 11% from $31.5 billion as at December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “Our AUM growth during the quarter was driven by surging gold prices and strong inflows to our physical gold and silver strategies. During the first three months of the year, we benefited from over $3.1 billion of market value appreciation. We also delivered approximately $407 million of net flows. Subsequent to quarter-end, we generated another $816 million of net flows, primarily into our flagship Sprott Physical Gold Trust...

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 Portfolio Decision to Prioritize Cemsidomide Development; C4T to Seek Partnership Opportunities to Advance BRAF Program CFT8919 Phase 1 Trial Continues to Advance in Partnership with Betta Pharmaceuticals; Discovery Platform Achieves Two Preclinical Milestones Under the Roche Collaboration Cash, Cash Equivalents and Marketable Securities of $234.7 Million...

— First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million — — Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity — — U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 — — Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 — — Cash on-hand expected to support planned operations into 2027 — — Management to host conference call today at 8:00 a.m. ET — BOSTON, May 07, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...

— Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 — — 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 — — Raises 2025 guidance; expects to generate $255 – $265 million in net product revenue and cash flow of $30 – $40 million, driven by 3,400 – 3,600 patients on LUMRYZ by year end — — Federal Circuit ruled in Avadel’s favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) —         — On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ...

– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. “During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “For VG-3927, we reported positive Phase 1 data in January 2025...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 millionIncrease in demand offset by inventory dynamics and funding shortages at co-pay assistance programsReceived U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGN On track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025 Cash and cash equivalents of $358.4 million as of March 31, 2025; projected revenues and cash expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30...

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres’ live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions in support of further development in allo-HSCT and potential expansion into other target populations Conference call at 8:30 a.m. ET today CAMBRIDGE,...

Revenue:$304.1 million for Q1 2025Net Income:$41.7 million for Q1 2025Earnings per common unit:$1.38 for Q1 2025Net cash from operating activities:$156.6 million for Q1 2025EBITDA:$147.6 million for Q1 2025Returning capital to unitholders:423,984 common units repurchased in 2025 (through May 1st) for $16.1 million $0.05 per unit cash distribution for Q1 2025; $0.20 per unit annualizedSales and purchases YTD 2025:$34.7 million gross sale proceeds from sale of three vessels; average age of 19.1 years Four newbuilding vessels delivered$  3.4 billion contracted revenue as of April 2025PIRAEUS, Greece, May 07, 2025 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo and tanker vessels, today reported its financial results...

MALVERN, Pa., May 07, 2025 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended March 29, 2025. Highlights1Q 2025 revenues of $715.2 million Gross margin was 19.0% and included the negative impact of approximately 200 basis points related to the addition of Newport 1Q 2025 loss per share of ($0.03) 1Q 2025 book-to-bill of 1.08 with book-to-bill of 1.12 for semiconductors and 1.04 for passive components Backlog at quarter end was 4.7 months“Market signals, which continued from the fourth quarter, indicate that much of the channel inventory that overhung the market has normalized. We executed well during the first quarter on our strategic levers to drive...

First quarter revenue of $753 million, up 7.0%, and up 7.9% on an organic constant currency (OCC) basis. Net income of $232 million, up 5.9%. Adjusted EBITDA, a non-GAAP measure, of $417 million, up 9.5%, and up 9.5% on an OCC basis. Diluted GAAP earnings per share of $1.65, up 8.6%. Diluted adjusted EPS, a non-GAAP measure, of $1.73, up 6.1%.JERSEY CITY, N.J., May 07, 2025 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, today announced results for the first quarter ended March 31, 2025. The earnings release is available on the company’s Investor Relations website at investor.verisk.com. Lee Shavel, President and CEO, Verisk:“I am pleased to share that 2025 is off to a solid start at Verisk as we delivered broad-based top line growth across underwriting and claims and healthy...